β-Lapachone promotes the recruitment and polarization of tumor-associated neutrophils (TANs) toward an antitumor (N1) phenotype in NQO1-positive cancers

References

• Mayadas TN, Cullere X, Lowell CA. The multifaceted functions of neutrophils. Annu Rev Pathol. 2014;9(1):181–17. doi:10.1146/annurev-pathol-020712-164023.
   PubMed Web of Science ®Google Scholar
• Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013;13(3):159–175. doi:10.1038/nri3399.
   PubMed Web of Science ®Google Scholar
• Ley K, Hoffman HM, Kubes P, Cassatella MA, Zychlinsky A, Hedrick CC, Catz SD. Neutrophils: New insights and open questions. Sci Immunol. 2018;3(30). doi:10.1126/sciimmunol.aat4579.
   PubMed Web of Science ®Google Scholar
• Nicolás-Ávila JÁ, Adrover JM, Hidalgo A. Neutrophils in homeostasis, immunity, and cancer. Immunity. 2017;46(1):15–28. doi:10.1016/j.immuni.2016.12.012.
   PubMed Web of Science ®Google Scholar
• Fridlender ZG, Albelda SM. Tumor-associated neutrophils: friend or foe? Carcinogenesis. 2012;33(5):949–955. doi:10.1093/carcin/bgs123.
   PubMed Web of Science ®Google Scholar
• Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer. 2020;20(9):485–503. doi:10.1038/s41568-020-0281-y.
   PubMed Web of Science ®Google Scholar
• Zahid KR, Raza U, Tumbath S, Jiang L, Xu W, Huang X. Neutrophils: Musketeers against immunotherapy. Front Oncol. 2022;12. doi:10.3389/fonc.2022.975981.
   Web of Science ®Google Scholar
• Eruslanov EB, Bhojnagarwala PS, Quatromoni JG, Stephen TL, Ranganathan A, Deshpande C, Akimova T, Vachani A, Litzky L, Hancock WW. et al. Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest. 2014;124(12):5466–5480. doi:10.1172/JCI77053.
   PubMed Web of Science ®Google Scholar
• Mensurado S, Rei M, Lança T, Ioannou M, Gonçalves-Sousa N, Kubo H, Malissen M, Papayannopoulos V, Serre K, Silva-Santos B. et al. Tumor-associated neutrophils suppress pro-tumoral IL-17+ γδ T cells through induction of oxidative stress. PLOS Biol. 2018;16(5):e2004990. doi:10.1371/journal.pbio.2004990.
   PubMed Web of Science ®Google Scholar
• Singhal S, Bhojnagarwala PS, O’Brien S, Moon EK, Garfall AL, Rao AS, Quatromoni JG, Stephen TL, Litzky L, Deshpande C. et al. Origin and role of a subset of tumor-associated neutrophils with antigen-presenting cell features in early-stage human lung cancer. Cancer Cell. 2016;30(1):120–135. doi:10.1016/j.ccell.2016.06.001.
   PubMed Web of Science ®Google Scholar
• Granot Z, Henke E, Comen EA, King TA, Norton L, Benezra R. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell. 2011;20(3):300–314. doi:10.1016/j.ccr.2011.08.012.
   PubMed Web of Science ®Google Scholar
• Clark RA, Klebanoff SJ. Neutrophil-mediated tumor cell cytotoxicity: role of the peroxidase system. J Exp Med. 1975;141(6):1442–1447. doi:10.1084/jem.141.6.1442.
   PubMed Web of Science ®Google Scholar
• Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology. 2008;73(3–4):215–220. doi:10.1159/000127412.
   Web of Science ®Google Scholar
• Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938–945. doi:10.1038/nm.3909.
   PubMed Web of Science ®Google Scholar
• Sagiv JY, Michaeli J, Assi S, Mishalian I, Kisos H, Levy L, Damti P, Lumbroso D, Polyansky L, Sionov RV. et al. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. Cell Rep. 2015;10(4):562–573. doi:10.1016/j.celrep.2014.12.039.
   PubMed Web of Science ®Google Scholar
• Di Carlo E, Forni G, Lollini P, Colombo MP, Modesti A, Musiani P. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood. 2001;97(2):339–345. doi:10.1182/blood.V97.2.339.
   PubMed Web of Science ®Google Scholar
• Andzinski L, Kasnitz N, Stahnke S, Wu C-F, Gereke M, von Köckritz-Blickwede M, Schilling B, Brandau S, Weiss S, Jablonska J. Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human. Int J Cancer. 2016;138(8):1982–1993. doi:10.1002/ijc.29945.
   PubMed Web of Science ®Google Scholar
• Shaul ME, Levy L, Sun J, Mishalian I, Singhal S, Kapoor V, Horng W, Fridlender G, Albelda SM, Fridlender ZG. Tumor-associated neutrophils display a distinct N1 profile following TGFβ modulation: A transcriptomics analysis of pro- vs. antitumor TANs. Antitumor TANs, OncoImmunol. 2016;5(11):e1232221. doi:10.1080/2162402X.2016.1232221.
   PubMed Web of Science ®Google Scholar
• Blaisdell A, Crequer A, Columbus D, Daikoku T, Mittal K, Dey SK, Erlebacher A. Neutrophils oppose uterine epithelial carcinogenesis via debridement of hypoxic tumor cells. Cancer Cell. 2015;28(6):785–799. doi:10.1016/j.ccell.2015.11.005.
   PubMed Web of Science ®Google Scholar
• Gruijs M, Sewnath CAN, van Egmond M. Therapeutic exploitation of neutrophils to fight cancer. Semin Immunol. 2021;57:101581. doi:10.1016/j.smim.2021.101581.
   PubMed Web of Science ®Google Scholar
• Cui C, Chakraborty K, Tang XA, Zhou G, Schoenfelt KQ, Becker KM, Hoffman A, Chang Y-F, Blank A, Reardon CA. et al. Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis. Cell. 2021;184(12):3163–3177.e3121. doi:10.1016/j.cell.2021.04.016.
   PubMed Web of Science ®Google Scholar
• Nie P, Zhang W, Meng Y, Lin M, Guo F, Zhang H, Tong Z, Wang M, Chen F, An L. et al. AYAP/TAZ-CD54 axis is required for CXCR2−CD44− tumor-specific neutrophils to suppress gastric cancer. Protein & Cell. 2023;14(7):515–533. doi:10.1093/procel/pwac045.
   Web of Science ®Google Scholar
• Linde IL, Prestwood TR, Qiu J, Pilarowski G, Linde MH, Zhang X, Shen L, Reticker-Flynn NE, Chiu DK, Sheu LY. et al. Neutrophil-activating therapy for the treatment of cancer. Cancer Cell. 2023;41(2):356–372.e310. doi:10.1016/j.ccell.2023.01.002.
   PubMed Web of Science ®Google Scholar
• Matlung HL, Babes L, Zhao XW, van Houdt M, Treffers LW, van Rees DJ, Franke K, Schornagel K, Verkuijlen P, Janssen H. et al. Neutrophils kill antibody-opsonized cancer cells by trogoptosis. Cell Rep. 2018;23(13):3946–3959.e3946. doi:10.1016/j.celrep.2018.05.082.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Guoqiang L, Sun M, Lu X. Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment. Cancer Biol Med. 2020;17(1):32–43. doi:10.20892/j.issn.2095-3941.2019.0372.
   PubMed Web of Science ®Google Scholar
• Kaisar-Iluz N, Arpinati L, Shaul ME, Mahroum S, Qaisi M, Tidhar E, Fridlender ZG. The bilateral interplay between cancer immunotherapies and neutrophils’ phenotypes and sub-populations. Phenotypes And Sub-Popul Cells. 2022;11(5):783. doi:10.3390/cells11050783.
   Google Scholar
• Huang X, Motea EA, Moore ZR, Yao J, Dong Y, Chakrabarti G, Kilgore JA, Silvers MA, Patidar PL, Cholka A. et al. Leveraging an NQO1 bioactivatable drug for tumor-selective use of Poly(ADP-ribose) Polymerase Inhibitors. Cancer Cell. 2016;30(6):940–952. doi:10.1016/j.ccell.2016.11.006.
   PubMed Web of Science ®Google Scholar
• Zhang K, Chen D, Ma K, Wu X, Hao H, Jiang S. NAD(P)H: Quinone oxidoreductase 1 (NQO1) as a therapeutic and diagnostic target in cancer. J Med Chem. 2018;61(16):6983–7003. doi:10.1021/acs.jmedchem.8b00124.
   PubMed Web of Science ®Google Scholar
• Zhao W, Jiang L, Fang T, Fang F, Liu Y, Zhao Y, You Y, Zhou H, Su X, Wang J. et al. β-lapachone selectively kills hepatocellular carcinoma cells by targeting NQO1 to induce extensive DNA Damage and PARP1 Hyperactivation. Front Oncol. 2021;11:747282. doi:10.3389/fonc.2021.747282.
   PubMed Web of Science ®Google Scholar
• Huang X, Dong Y, Bey EA, Kilgore JA, Bair JS, Li LS, Patel M, Parkinson EI, Wang Y, Williams NS. et al. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis. Cancer Res. 2012;72(12):3038–3047. doi:10.1158/0008-5472.CAN-11-3135.
   PubMed Web of Science ®Google Scholar
• Jiang L, Liu Y, Su X, Wang J, Zhao Y, Tumbath S, Kilgore JA, Williams NS, Chen Y, Wang X. et al. KP372-1-induced AKT hyperactivation blocks DNA repair to synergize with parp inhibitor rucaparib via Inhibiting FOXO3a/GADD45α pathway. Front Oncol. 2022;12:976292. doi:10.3389/fonc.2022.976292.
   PubMed Web of Science ®Google Scholar
• Su X, Wang J, Jiang L, Chen Y, Lu T, Mendonca MS, Huang X. PCNA inhibition enhances the cytotoxicity of β-lapachone in NQO1-Positive cancer cells by augmentation of oxidative stress-induced DNA damage. Cancer Lett. 2021;519:304–314. doi:10.1016/j.canlet.2021.07.040.
   PubMed Web of Science ®Google Scholar
• Chang MC, Mahar R, McLeod MA, Giacalone AG, Huang X, Boothman DA, Merritt ME. Synergistic effect of β-lapachone and aminooxyacetic acid on central metabolism in breast cancer. Nutrients. 2022;14(15):3020. doi:10.3390/nu14153020.
   PubMed Web of Science ®Google Scholar
• Jiang L, Liu Y, Tumbath S, Boudreau MW, Chatkewitz LE, Wang J, Su X, Zahid KR, Li K, Chen Y. et al. Isopentyl-Deoxynboquinone induces mitochondrial dysfunction and g2/m phase cell cycle arrest to selectively kill NQO1-positive pancreatic cancer cells. Antioxidants & Redox Signaling. 2023; doi:10.1089/ars.2022.0224.
   Web of Science ®Google Scholar
• Li X, Liu Z, Zhang A, Han C, Shen A, Jiang L, Boothman DA, Qiao J, Wang Y, Huang X. et al. NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance. Nat Commun. 2019;10(1):3251. doi:10.1038/s41467-019-11238-1.
   PubMedGoogle Scholar
• Pink JJ, Planchon SM, Tagliarino C, Varnes ME, Siegel D, Boothman DA. NAD(P)H: Quinone oxidoreductase activity is the principal determinant of β-lapachone cytotoxicity *. J Biol Chemistry. 2000;275(8):5416–5424. doi:10.1074/jbc.275.8.5416.
   PubMed Web of Science ®Google Scholar
• Swamydas M, Luo Y, Dorf ME, Lionakis MS. Isolation of mouse neutrophils. Current Protoc Immunol. 2015;110(1):.3.20.21–.23.20.15. doi:10.1002/0471142735.im0320s110.
   Google Scholar
• Aarts CEM, Hiemstra IH, Béguin EP, Hoogendijk AJ, Bouchmal S, van Houdt M, Tool ATJ, Mul E, Jansen MH, Janssen H. et al. Activated neutrophils exert myeloid-derived suppressor cell activity damaging T cells beyond repair. Blood Adv. 2019;3(22):3562–3574. doi:10.1182/bloodadvances.2019031609.
   PubMed Web of Science ®Google Scholar
• Sionov RV, Assi S, Gershkovitz M, Sagiv JY, Polyansky L, Mishalian I, Fridlender ZG, Granot Z. Isolation and characterization of neutrophils with anti-tumor properties. J Vis Exp. 2015;(100):e52933. doi:10.3791/52933-v.
   PubMed Web of Science ®Google Scholar
• Luo Y, Dorf ME. Isolation of Mouse Neutrophils. Current Protoc Immunol. 1997;22(1):.3.20.21–.23.20.26. doi:10.1002/0471142735.im0320s22.
   Google Scholar
• Chan EC, Ren C, Xie Z, Jude J, Barker T, Koziol-White CA, Ma M, Panettieri RA Jr., Wu D, Rosenberg HF. et al. Regulator of G protein signaling 5 restricts neutrophil chemotaxis and trafficking. J Biol Chem. 2018;293(33):12690–12702. doi:10.1074/jbc.RA118.002404.
   PubMed Web of Science ®Google Scholar
• Podhorecka M, Skladanowski A, Bozko P. H2AX phosphorylation: its role in DNA damage response and cancer therapy. J Nucleic Acids. 2010;2010:1–9. doi:10.4061/2010/920161.
   Google Scholar
• Lee PY, Wang JX, Parisini E, Dascher CC, Nigrovic PA. Ly6 family proteins in neutrophil biology. J Leukoc Biol. 2013;94(4):585–594. doi:10.1189/jlb.0113014.
   PubMed Web of Science ®Google Scholar
• Hasenberg A, Hasenberg M, Männ L, Neumann F, Borkenstein L, Stecher M, Kraus A, Engel DR, Klingberg A, Seddigh P. et al. Catchup: a mouse model for imaging-based tracking and modulation of neutrophil granulocytes. Nat Methods. 2015;12(5):445–452. doi:10.1038/nmeth.3322.
   PubMed Web of Science ®Google Scholar
• Mohamad Zaki NH, Shiota J, Calder AN, Keeley TM, Allen BL, Nakao K, Samuelson LC, Razumilava N. C-X-C motif chemokine ligand 1 induced by Hedgehog signaling promotes mouse extrahepatic bile duct repair after acute injury. Hepatology. 2022;76(4):936–950. doi:10.1002/hep.32492.
   PubMed Web of Science ®Google Scholar
• Olofsen PA, Stip MC, Jansen JHM, Chan C, Nederend M, Tieland RG, Tsioumpekou M, Leusen JHW, Effective L-T. Neutrophil depletion using a murinized anti-ly-6G 1A8 antibody. Cells. 2022;11(21):3406. doi:10.3390/cells11213406.
   PubMed Web of Science ®Google Scholar
• Oberg H-H, Wesch D, Kalyan S, Kabelitz D. Regulatory Interactions between neutrophils, tumor cells and T cells. Front Immunol. 2019;10. doi:10.3389/fimmu.2019.01690.
   Web of Science ®Google Scholar
• Michaeli J, Shaul ME, Mishalian I, Hovav A-H, Levy L, Zolotriov L, Granot Z, Fridlender ZG. Tumor-associated neutrophils induce apoptosis of non-activated CD8 T-cells in a TNFα and NO-dependent mechanism, promoting a tumor-supportive environment. OncoImmunology. 2017;6(11):e1356965. doi:10.1080/2162402X.2017.1356965.
   PubMed Web of Science ®Google Scholar
• Giese MA, Hind LE, Huttenlocher A. Neutrophil plasticity in the tumor microenvironment. Blood. 2019;133(20):2159–2167. doi:10.1182/blood-2018-11-844548.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao Q, Zhao B, Zheng Y, Zhuang Q, Liao N, Wang P, Cai Z, Zhang D, Zeng Y. et al. Remodeling tumor-associated neutrophils to enhance dendritic cell-based hcc neoantigen nano-vaccine efficiency. Adv Sci. 2022;9(11):2105631. doi:10.1002/advs.202105631.
   Web of Science ®Google Scholar
• Ohms M, Möller S, Laskay T. An Attempt to Polarize Human Neutrophils Toward N1 and N2 Phenotypes in vitro. Front Immunol. 2020;11:532. doi:10.3389/fimmu.2020.00532.
   PubMed Web of Science ®Google Scholar
• Huebener P, Pradere JP, Hernandez C, Gwak GY, Caviglia JM, Mu X, Loike JD, Schwabe RF, Antoine DJ, Schwabe RF. The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis. J Clin Invest. 2015;125(2):539–550. doi:10.1172/JCI76887.
   PubMed Web of Science ®Google Scholar
• Venereau E, Casalgrandi M, Schiraldi M, Antoine DJ, Cattaneo A, Marchis FD, Liu J, Antonelli A, Preti A, Raeli L. et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med. 2012;209(9):1519–1528. doi:10.1084/jem.20120189.
   PubMed Web of Science ®Google Scholar
• Beg MS, Huang X, Silvers MA, Gerber DE, Bolluyt J, Sarode V, Fattah F, Deberardinis RJ, Merritt ME, Xie X-J. et al. Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer. J Surg Oncol. 2017;116(1):83–88. doi:10.1002/jso.24624.
   PubMed Web of Science ®Google Scholar
• Gerber DE, Beg MS, Fattah F, Frankel AE, Fatunde O, Arriaga Y, Dowell JE, Bisen A, Leff RD, Meek CC. et al. Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis. Br J Cancer. 2018;119(8):928–936. doi:10.1038/s41416-018-0278-4.
   PubMed Web of Science ®Google Scholar
• Rapoport BL, Anderson R. Realizing the Clinical Potential of Immunogenic cell death in cancer chemotherapy and radiotherapy. Int J Mol Sci. 2019;20(4):959. doi:10.3390/ijms20040959.
   PubMed Web of Science ®Google Scholar
• Gamrekelashvili J, Greten TF, Korangy F. Immunogenicity of necrotic cell death. Cell Mol Life Sci. 2015;72(2):273–283. doi:10.1007/s00018-014-1741-x.
   PubMed Web of Science ®Google Scholar
• Kaltenmeier C, Simmons RL, Tohme S, Yazdani HO. Neutrophil extracellular traps (NETs) in cancer metastasis. Cancers Basel. 2021;13(23):6131. doi:10.3390/cancers13236131.
   PubMed Web of Science ®Google Scholar
• Hadjigol S, Shah BA, O’Brien-Simpson NM. The ‘danse macabre’—neutrophils the interactive partner affecting oral cancer outcomes. Front Immunol. 2022;13. doi:10.3389/fimmu.2022.894021.
   PubMed Web of Science ®Google Scholar
• Minns D, Smith KJ, Hardisty G, Rossi AG, Gwyer Findlay E. The outcome of neutrophil-t cell contact differs depending on activation status of both cell types. Front Immunol. 2021;12. doi:10.3389/fimmu.2021.633486.
   Web of Science ®Google Scholar
• Pylaeva E, Lang S, Jablonska J. The essential role of type i interferons in differentiation and activation of tumor-associated neutrophils. Front Immunol. 2016;7. doi:10.3389/fimmu.2016.00629.
   PubMed Web of Science ®Google Scholar
• Liu Q, Hao Y, Du R, Hu D, Xie J, Zhang J, Deng G, Liang N, Tian T, Käsmann L. et al. Radiotherapy programs neutrophils to an antitumor phenotype by inducing mesenchymal-epithelial transition. Transl Lung Cancer Res. 2021;10(3):1424–1443. doi:10.21037/tlcr-21-152.
   PubMed Web of Science ®Google Scholar
• Hu J, Pan M, Wang Y, Zhu Y, Wang M. Functional plasticity of neutrophils after low- or high-dose irradiation in cancer treatment – a mini review. Front Immunol. 2023;14. doi:10.3389/fimmu.2023.1169670.
   Web of Science ®Google Scholar
• Xiong S, Dong L, Cheng L. Neutrophils in cancer carcinogenesis and metastasis. J Hematol Oncol. 2021;14(1):173. doi:10.1186/s13045-021-01187-y.
   PubMed Web of Science ®Google Scholar
• Orlova VV, Choi EY, Xie C, Chavakis E, Bierhaus A, Ihanus E, Ballantyne CM, Gahmberg CG, Bianchi ME, Nawroth PP. et al. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. Embo J. 2007;26(4):1129–1139. doi:10.1038/sj.emboj.7601552.
   PubMed Web of Science ®Google Scholar
• Governa V, Trella E, Mele V, Tornillo L, Amicarella F, Cremonesi E, Muraro MG, Xu H, Droeser R, Däster SR. et al. The interplay between neutrophils and CD8(+) T cells improves survival in human colorectal cancer. Clin Cancer Res. 2017;23(14):3847–3858. doi:10.1158/1078-0432.CCR-16-2047.
   PubMed Web of Science ®Google Scholar